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ABSTRACT: In recent years, cation-chloride cotransporters (CCCs) have drawn attention in the medical 
neuroscience research. CCCs include the family of Na+-coupled Cl– importers (NCC, NKCC1, and NKCC2), K+-
coupled Cl– exporters (KCCs), and possibly polyamine transporters (CCC9) and CCC interacting protein (CIP1). 
For decades, CCCs have been the targets of several commonly used diuretic drugs, including 
hydrochlorothiazide, furosemide, and bumetanide. Genetic mutations of NCC and NKCC2 cause congenital renal 
tubular disorders and lead to renal salt-losing hypotension, secondary hyperreninemia, and hypokalemic 
metabolic alkalosis. New studies reveal that CCCs along with their regulatory WNK (Kinase with no lysine (K)), 
and SPAK (Ste20-related proline-alanine-rich kinase)/ OSR1(oxidative stress-responsive kinase-1) are essential 
for regulating cell volume and maintaining ionic homeostasis in the nervous system, especially roles of the WNK-
SPAK-NKCC1 signaling pathway in ischemic brain injury and hypersecretion of cerebrospinal fluid in post-
hemorrhagic hydrocephalus. In addition, disruption of Cl– exporter KCC2 has an effect on synaptic inhibition, 
which may be involved in developing pain, epilepsy, and possibly some neuropsychiatric disorders. Interference 
with KCC3 leads to peripheral nervous system neuropathy as well as axon and nerve fiber swelling and psychosis. 
The WNK-SPAK/OSR1-CCCs complex emerges as therapeutic targets for multiple neurological diseases. This 
review will highlight these new findings. 
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Maintaining intracellular ionic homeostasis is essential 
for physiological function in all cells. A family of 
electroneutral transporters, the SLC12A family of CCCs 
(cation-chloride cotransporters), and their upstream 
regulatory serine-threonine kinases, the WNK (Kinase 
with no lysine (K)), SPAK (Ste20-related proline-alanine-
rich kinase) as well as OSR1 (oxidative stress-responsive 
kinase-1), play integral roles in the regulation of 
intracellular Na+, K+, and Cl– homeostasis as well as cell 
volume homeostasis [1-3]. The CCC family is comprised 
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of the Na+, K+-coupled Cl– importers (NCC, NKCC1, and 
NKCC2) and the K+-coupled Cl–  exporters (KCC1-4) [4, 
5]. Isoforms of WNK are phosphorylated (activated) in 
response to osmotic stress or when intracellular Cl– levels 
are low, and subsequently phosphorylate the related 
downstream kinases SPAK and/or OSR1 [6, 7]. Activated 
SPAK and/or OSR1 in turn stimulates NCC, NKCC1, 
NKCC2 via protein phosphorylation, but inhibits KCCs 
(with phosphorylation), via a reciprocal regulatory 
mechanism [8]. The inverse regulation of these ion 
cotransporters is driven by the same kinase-phosphatase 
signaling pathway to coordinate cellular Cl– efflux and 
influx in the cells to maintain Cl– homeostasis and avoid 
unnecessary ATP consumption. Generally, NKCC1, 
NKCC2, and NCC mediate Na+, K+, and Cl− influx, while 
KCC1-4 mediate K+ and Cl− efflux [9]. Abnormal 
function of the SLC12A family members was first 
associated with kidney dysfunction and diseases. 
Mutations of these CCCs can cause congenital renal 
tubular disorders such as renal salt-wasting syndromes 
[Gitelman syndrome (GS) and Bartter syndrome (BS)], 
and lead to secondary hyperaldosteronism and 
hypokalemic metabolic alkalosis (Table 1). Both GS and 
BS are caused by autosomal recessive gene mutations of 
NCC in the distal convoluted tubules (DCT) and NKCC2 
in the thick ascending limb (TAL) of the loop of Henle 
(Table 1) [10]. BS is divided into 5 types, each with 
different causes. Type I BS is caused by a forementioned 
SLC12A mutation (NKCC2) [11]. Other causes of BS 
include mutations in the potassium voltage-gated channel 
subfamily J member 1 (KCNJ1) for Type II BS, chloride 
channel Kb (ClC-Kb) for Type III BS, Bartter syndrome, 
infantile, with sensorineural deafness (BSND) for Type IV 
BS, and calcium-sensing receptor (CaSR) for Type V BS 
[11]. All of these disorders are caused by the disruption of 
ion homeostasis [12, 13]. New studies suggest that the 
WNK-SPAK/OSR1-CCC pathway is also involved in 
neurological diseases such as ischemic stroke and 
neuropathy [14-19]. This review will give readers an 
update on the emerging roles of WNK-SPAK/OSR1-CCC 
signaling pathway in neurological diseases.  
 
WNK-SPAK/OSR1 kinase complex and Cl- 
cotransporters in cell volume regulation in the nervous 
system  
 
Changes of intracellular osmolarity under normal 
physiological extracellular osmotic pressure (isosmotic 
stress) or anisosmotic volume stress (under hypertonic 
/hypotonic extracellular osmolality conditions) can 
trigger cellular responses in vertebrate cells to regulate 
volume [20, 21]. In hypotonic extracellular conditions, 
water enters into cells and causes cell swelling, which 
triggers regulatory volume decrease (RVD), a homeostatic 
counter-response [22]. RVD results from the efflux of K+ 
and Cl− via KCCs (KCC1, KCC3, and KCC4), and/or via 
K+ and Cl− channels along with water. The canonical 
volume-regulated KCCs are for the most part inactive 
under isotonic conditions but activate in response to cell 
swelling [13, 14]. On the contrary, cell shrinkage due to 
hypertonic conditions elicits regulatory volume increase 
(RVI) [20], which results in Na+ and Cl– influx via Na+ 
channels, activation of NKCC1, or Na+/H+ exchange. 
Activation of NKCC1 and/or reduction of KCC function 
can cause an increase in intracellular Na+ and Cl– levels, 
which can result in isosmotic cell swelling [23]. Cell 
swelling due to either isosmotic and anisosmotic 
conditions could contribute to swelling in neurons, glia, 
and capillary endothelial cells of the blood-brain barrier 
(BBB), which can collectively contribute to brain edema 
and will be discussed further [24]. 
The WNKs are a serine/threonine kinase family 
encoded by the genes WNK1-4 [25]. In the context of 
volume regulation, protein phosphorylation effectuated 
by the WNK-SPAK kinase pathway activates NKCC1 but 
simultaneously inhibits KCCs, whereas protein 
dephosphorylation inhibits NKCC1 and activates the 
KCCs [26]. The major phosphoregulatory sites have been 
identified at the N-terminus of NKCC1 at Thr203, Thr207 
and Thr212, and in the C-terminus of KCC1-4 at Thr991 in 
KCC3 and at Thr906 in KCC2 in human, sharks and mice 
[4, 8]. Sites homologous to KCC3 Thr991 and Thr1048 
residues, Site-1 (Thr991) and Site-2 (Thr1048), are 
phosphorylated in all human KCCs [8]. Substitution of 
these Thr residues (with Ala) causes KCC2 and KCC3 
activation due to inhibition of phosphorylation [27, 28]. 
Recently, a functional kinomics study showed the WNK3-
SPAK complex to be vital for regulating phosphorylation 
of KCC3 at Site-1 and Site-2 [26].  
SPAK/OSR1 interacts with KCC1-4 and NKCC1 by 
means of a specific conserved carboxyl-terminal (CCT) 
domain [26, 29, 30]. SPAK’s CCT domain is recognized 
by the Arg-The-Xaa-Val/Ile (RFXV/I) domain in the 
amino-terminal of KCC1-4 and NKCC1-2.  KCC2 
subtype KCC2b has no RFXV/I motif, so SPAK 
overexpression decreases the transport activity of KCC2a 
but not KCC2b [5, 31]. This ability of SPAK/OSR1 (via 
CCT) to attach to both the WNKs and CCCs (upstream 
and downstream) is essential for coordinating cellular 
cotransporter activity in isosmotic or hyperosmotic 
conditions [30, 32]. WNK’s binding to SPAK/OSR1 
allows the phosphorylation of residues found in the T-loop 
of the SPAK catalytic domain [30, 32]. This process is 
crucial for SPAK’s ability to phosphorylate (inhibit) 
Thr991/ Thr1048 in KCC3 and Thr906 in KCC2 while 
phosphorylating (activating) NKCC1 at 
Thr203/Thr207/Thr212 in response to cellular shrinkage and 
hypertonicity (Fig. 1) [5]. NKCC1’s phosphorylation and 
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activation by SPAK/OSR1 in hypertonic conditions is a 
vital component of RVI [5, 33], which leads to influx of 
Na+, K+ and Cl− along with water to achieve cell volume 
recovery (Fig. 1). Under hypotonic extracellular 
conditions, water enters the cells and causes cell swelling, 
subsequently triggering a counter volume regulation 
response, i.e., RVD. In this condition, the WNK-
SPAK/OSR1 pathway remains inactive and inhibits 
NKCC1 activity (Fig. 1). Phosphatase-mediated 
dephosphorylation of KCCs stimulates their activity and 
leads to efflux of K+ and Cl− along with water, and thus 
decreases cell volume (Fig. 1). Therefore, 
pharmacological or genetic antagonism of WNK-
SPAK/OSR1 enables cellular chloride expulsion by 
simultaneously decreasing phosphorylation of NKCC1 
and the KCCs, and thus acute cell swelling caused by 
osmotic stress may be prevented or the cerebral edema 
caused by energy failure diseases may be mitigated [26, 
34, 35].  
 
Table 1. Phenotypes of transgenic knockout (KO) mice involving WNK-SPAK/OSR1-CCC complex 
 
Protein Co-
transport 
ions 
Tissue and Subcellular 
Distribution 
Relating to 
human diseases 
Phenotypes of KO/KI mice Refs. 
SLC12A1 
(NKCC2) 
Na+, K+, 
Cl– 
Kidney-specific (TAL); 
apical plasma membrane; 
hypothalamo-neurohypophyseal 
system 
Bartter syndrome Severe hypotension, hypokalemia, 
hypercalciuria, metabolic alkalosis 
[80-82] 
SLC12A2 
(NKCC1) 
Na+, K+, 
Cl– 
Ubiquitous; 
basolateral plasma membrane 
None Sensorineural deafness, 
 alterations in endolymph secretion,  
reduced saliva production, 
 sensory perception abnormalities and infertility 
[58, 83-
86] 
SLC12A3 
(NCC) 
Na+, Cl– Kidney-specific (DCT);  
bone? 
apical plasma membrane 
Gitelman 
syndrome 
Hypotension, 
hypocalciuria, 
hypomagnesemia, 
hypokalemia 
[87-89] 
SLC12A4 
(KCC1) 
K+, Cl– Ubiquitous None No phenotype [90] 
SLC12A5 
(KCC2) 
K+, Cl– Neuron-specific; 
basolateral plasma membrane (?) 
Epilepsy 
 
Complete – death due to absent respiratory 
drive.   
 incomplete KO (5%of function remains).  
Status epilepticus,   
death ± 15 days after birth. 
[91, 92] 
SLC12A6 
(KCC3) 
K+, Cl– Widespread Andermann 
syndrome 
Knockout mice recapitulate the  
locomotion and neuropathy phenotypes 
 and demonstrate axonal swelling 
[92, 93] 
SLC12A7 
(KCC4) 
K+, Cl– Widespread; 
basolateral plasma membrane (?) 
None Sensorineural deafness  
and renal tubular acidosis 
[94, 95] 
SPAK -- Ubiquitous No report in 
human, but 
resemble Gitelman 
syndrome in mice  
KO mice exhibited hypotension and 
recapitulated Gitelman syndrome with 
hypokalemia, hypomagnesemia, and 
hypocalciuria; higher nociceptive threshold and 
increased anxiety  
[12, 66] 
OSR1 -- Ubiquitous No report in 
human, but 
resemble Bartter 
syndrome in mice  
Global KO – die in utero. Heterozygous KO – 
low BP. Kidney tubule-specific KO – normal 
BP with hypercalciuria and hypokalemia  
[96, 97] 
WNK1 -- Ubiquitous HSANⅡ; 
PHAII 
Less susceptible to hypersensitivity to cold and 
mechanical stimuli after peripheral nerve injury 
[73, 75, 
96, 98, 
99] 
WNK2 -- Prominently expressed in brain 
neurons；fetal brain and heart 
No report No report [100, 
101] 
WNK3 -- Ubiquitous Autistic disorder？ Mice exhibited less cytotoxic edema after 
MCAO; compensated elevation of 
WNK1/SPAK axis in the kidney 
[34, 65, 
72, 102]  
WNK4 -- Ubiquitous PHAII KO mice exhibited hypokalemia but 
normalcalciuria 
[99, 103] 
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Figure 1. Roles of CCC in cell volume regulation. Intracellular osmolarity changes trigger cellular responses for volume regulation. 
Under hypertonic extracellular conditions, water extrudes from the cells and causes cell shrinkage, triggering a counter-response of 
regulatory volume increase (RVI). In this condition, the WNK-SPAK/OSR1 pathway is activated and phosphorylates NKCC1 and 
KCCs, resulting in NKCC1activation and KCCs inhibition. This subsequently leads to influx of Na+, K+ and Cl− via NKCC1 along 
with water, thus restoring cell volume. On the contrary, cell swelling due to hypotonic stress elicits regulatory volume decrease 
(RVD), in which the WNK-SPAK/OSR1 pathway remains inactive and NKCC1 and KCCs are dephosphorylated. This results in 
NKCC1 inhibition but stimulation of KCCs, which lead to KCC-mediated efflux of K+ and Cl− along with water, and cell volume 
decrease. 
 
Activation of WNK-SPAK /OSR1 kinase complex by 
low intracellular Cl–   
 
The WNK kinases are not only effector kinases that work 
in conjunction with the SPAK/OSR1 kinases to regulate 
CCCs by phosphorylation, but may also serve as the 
intracellular Cl– sensors (potentially cell volume sensors) 
[6]. Cl– is a vital ion which is involved in the regulation 
of neuronal excitability and cell volume [20, 36]. Cl– 
stabilizes WNK1 in its inactive conformation and 
prevents kinase autophosphorylation by binding to 
WNK1’s catalytic site, which is situated at the DLG motif 
and the N-terminus of the activation loop [6]. Because 
WNK1 is sensitive to Cl–-mediated inhibition of 
autophosphorylation, it effectively serves as a Cl– 
concentration sensor [6]. Among WNK1-4, Cl– inhibits 
WNK4 kinase activity at lower concentrations than it 
inhibits activity of WNK1 or WNK3 [37]. In light of 
expression of WNK4 in the BBB endothelium and 
increased level in ischemic stroke of hypertensive rats 
[16], future studies are needed to elucidate roles of WNK4 
in the CNS, especially considering to its high sensitivity 
to [Cl]i. Developing inducible and cell-type specific 
WNK4 KO mice will be helpful to investigate these 
questions.  
Furthermore, the functions of SPAK and/or OSR1 are 
also sensitive to the changes in Cl– concentration [38]. In 
the adult central nervous system (CNS), GABA is one of 
the main inhibitory neurotransmitters, utilizing the 
activated ligand-gated, Cl−-permeable GABAA receptors 
(GABAARs) to propagate its fast synaptic hyperpolarizing 
effect [39]. When GABA binds to and activates the 
GABAA receptor, the Cl
– ions flow into the cell through 
the channel, resulting in hyperpolarization of the cell and 
suppression of the electrophysiological activity of the 
related neurons [39]. As opposed to NKCC1, increased 
KCC2 expression during brain maturation mediates Cl- 
extrusion and reduces [Cl-]i in neurons, which in turn 
favors GABAAR-mediated hyperpolarization in the 
mature CNS [40]. The low [Cl–]i maintained by KCC2 is 
required for GABA-mediated synaptic inhibition [41, 
42]. However, in developing neurons, responses actuated 
by GABAARs are depolarizing and sometimes excitatory, 
which are critical for synaptogenesis, neuronal 
proliferation, and migration [43, 44]. For example, there 
is a “excitatory-inhibitory developmental sequence” of 
GABA in the nervous system, which is closely related 
with the [Cl−]i [45-52]. Increase in expression and activity 
of WNK3 and OSR1 was believed to be the cause of 
disturbance of GABA-mediated neurotransmission in 
CNS and consequently schizophrenia [44, 46]. 
Neuropathic pain and spasticity resulting from spinal cord 
injury (SCI) are often associated with defective 
GABAergic function, mainly caused by impairment of 
KCC2 functionality [49, 53]. All these studies signal for 
importance of [Cl-]i in regulating WNK. In the peripheral 
nervous system (PNS), glia and neurons have a relatively 
higher [Cl–]i due to KCC3’s inhibition, elevated 
expression of NKCC1, and an absence of KCC2 [54, 55]. 
In response to this higher [Cl−]i, WNK can be deactivated 
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and lead to dephosphorylation of NKCC1 and KCC3, 
resulting in decreased NKCC1 expression and increased 
KCC3 expression and activation, which in turn reduce 
[Cl−]i and favors GABA-mediated hyperpolarization. 
Thus, neurons and glia of the PNS are more efficient in 
volume regulation and GABAergic circuit functions due 
to KCC3-mediated K+ and Cl– efflux and high-water 
permeability [56, 57]. Taken together, WNK-SPAK/ 
OSR1-mediated phosphoregulation of NKCC1/KCCs 
might be important for determining the molecular 
mechanisms in diseases characterized by neuronal 
hyperexcitability, such as stroke and epilepsy, where lack 
of GABA-mediated inhibition might be responsible for 
the excitatory effects.  
 
 
 
Figure 2. Illustration of the WNK-SPAK/OSR1-CCCs cascade in nervous and non-nervous system diseases. Mutations of E3 
ubiquitin ligase components cullin 3 (CUL3) and kelch-like 3 (KLHL3) were identified to cause Pseudohypoaldosteronism type II 
(PHAII) with increased WNK1 and WNK4 abundance in kidney. Gene mutations in WNK1 and WNK4 also cause PHAII with 
compromised cell volume homeostasis. In addition, osmotic stress can trigger WNK-SPAK/OSR1 complex activation, which leads 
to downstream phosphorylation of CCCs, especially stimulatory phosphorylation of NKCC1 and inhibitory phosphorylation of 
KCCs. Overstimulation of NKCC1 increases cytotoxic edema, enlarges infarction, and worsens neurobehavioral function in 
ischemic stroke. Hyperactive NKCC1 increases CSF secretion by the choroid plexus epithelium and causes post-hemorrhagic 
hydrocephalus after intraventricular hemorrhage. On the other hand, phosphorylation of KCC2 by WNK-SPAK/OSR1 decreases 
its Cl- efflux and reduces GABA-mediated inhibition of spinal nerve transmission and causes neuropathic pain. To date, no direct 
evidence links oxidative stress or inflammation to WNK activation in the nervous system. However, oxidative stress can directly 
activate SPAK/OSR1, which in turn regulates WNK activity, thus indirectly activates WNK; inflammation-induced stimulation of 
the WNK-SPAK/OSR1 pathway could also increase WNK activity. Dysfunction of KCC3, such as via KCC3 mutation, leads to 
compromised cell volume homeostasis and causes hereditary motor and sensory neuropathy with agenesis of the corpus callosum 
(HMSN/ACC), hearing loss and a reduced threshold for seizure. Hereditary sensory and autonomic neuropathy type II (HSANII) 
caused by HSN2 gene mutations leads to a loss-of-function for WNK1 activity. Taken together, the WNK-SPAK/OSR1-CCC 
signaling pathway emerges as a new therapeutic target for nervous and non-nervous system disorders. 
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Neurological deficits in transgenic mice with 
modifications of WNK-SPAK/OSR1-CCC signaling 
pathway   
 
In the past decade, establishment of specific gene 
knockout (KO) models or genetic knock-in (KI) mouse 
models significantly improved our understanding of the 
physiological function of the WNK-SPAK/OSR1-CCC 
pathway in the nervous system. Global NKCC1 KO mice 
exhibited seizure, hearing loss (due to loss of K- secretion 
in the inner ear and suppressed bumetanide-sensitive 86Rb 
uptake and chloride fluxes across the secretory 
epithelium), and slightly diminished blood pressure than 
wild-type (WT) animals (Table 1) [58]. KCC3 and KCC4 
are copiously expressed in both CNS and PNS, and 
mutations of them can cause various diseases [59]. Two 
KCC3 KO mouse models have been created for further 
exploration of the functions of KCC3 [60, 61]. Using 
homologous recombination truncating mutations to 
disrupt the SLC12A6 gene of KCC3 generates KCC3 KO 
mice (SLC12A6-/-) [60]. The second KCC3 KO mouse 
line was created by Boettger et al [61], as well as a 
spontaneous mutation in the Jackson Lab [62]. KCC3 KO 
mice (SLC12A6-/-) show discoordination and feebleness 
in the hind limbs 14 days after birth, as well as axonal 
swelling in the sciatic nerves, hypomyelination, 
demyelination, and fiber degeneration (Table 1) [63]. In 
two independent studies, nerve conduction impairment in 
KCC3 KO mice arose from the combination of impaired 
ionic clearance and axonal swelling in the sciatic nerve 
[63, 64]. Adult KCC3 KO mice showed reduced 
exploration of their environment and deafness in behavior 
tests due to abnormal inner ear cells [60, 61]. 
Furthermore, in cerebellar slice preparations (which 
express abundant KCC3), both WT and KCC3-null 
Purkinje cells exhibit swelling in hypotonic conditions but 
KCC3-null cells failed to normalize their volume after 
returning to isotonic conditions, suggesting that KCC3-
dependent RVD was impaired in KCC3 KO cells  [61]. 
Additionally, the seizure threshold of KCC3-null mice is 
lower than WT mice, which was detected by the patch-
clamp technique [61].  
 Inhibition of the WNK-SPAK-CCC cascade can 
reduce cellular swelling in ischemic stroke brains by 
concurrently inhibiting NKCC-mediated ionic influx and 
stimulating KCC-mediated ion efflux. WNK3 KO mice 
show normal weight, behavior, and growth [35, 65]. They 
exhibited less cytotoxic edema after ischemic stroke in the 
middle cerebral artery occlusion (MCAO) model [34]. 
However, both adult WNK3 KO and SPAK KO mice have 
impaired locomotor function (Table 1) [34]. Compared to 
their WT counterparts, SPAK KO mice display a higher 
nociceptive threshold [66]. They also exhibit increased 
thigmotaxis in the open field chamber and spend 
significantly longer periods of time in the dark area of the 
light/dark box, indicating an anxiety-like phenotype [66]. 
These findings suggest that WNK-SPAK-CCC signal 
pathway is important in regulating function of the nervous 
system, which may be through fine tuning of Cl- and cell 
volume homeostasis. 
 
The Cl- cotransporters and WNK-SPAK signaling 
pathway in ischemic brain edema and hypersecretion 
of cerebrospinal fluid (CSF) 
 
The WNK-SPAK-CCC signaling complex plays a role in 
regulating cell volume and ionic homeostasis in both the 
CNS and PNS. Considering the special physiology of the 
brain and skull, cell volume regulation in the CNS is 
especially important because slight volume changes can 
affect normal brain function and cause life-threatening 
problems [21]. Such as in ischemic stroke, activation of 
NKCC1 causes brain edema (isosmotic cell swelling via 
increasing the intracellular concentration of Na+ and Cl–) 
and brain injury [16, 67]. Brain edema can increase 
intracranial pressure, trigger herniation, or even cause 
death. In a recent experimental ischemic stroke study, 
WNK3 KO mice displayed significantly decreased 
cerebral swelling, axonal demyelination, and infarct 
volume as well as accelerated neurobehavioral recovery, 
compared to WT mice [35]. WNK3 KO mice have shown 
two swelling-associated components of ischemic cerebral 
edema to be mitigated: endothelial and perivascular 
cytotoxic edema of astrocytes [26]. These effects likely 
result from decreased NKCC1 activity and increased 
KCC3-mediated cellular Cl– efflux [26].  
The neuroprotective phenotypes conferred by WNK3 
KO were associated with a decrease in NKCC1 cell 
surface expression, reduced phosphorylation at NKCC1 
stimulatory sites (Thr203/Thr207/Thr212) and a decrease in 
stimulatory hyperphosphorylations of the SPAK/OSR1 
catalytic T-loop [35]. Compared to WT mice, WNK3 KO 
and SPAK KO (or SPAK heterozygous) mice showed 
more than a 50% reduction in infarct volume and 
associated cerebral edema after ischemic stroke. Cultured 
primary neurons and oligodendrocytes showed increased 
tolerance to in vitro ischemia with genetic inhibition of 
WNK3 or small interfering RNA knockdown of 
SPAK/OSR1 [34]. Therefore, WNK-SPAK-NKCC1 
complex inhibition has therapeutic potential for treating 
cerebral edema and ischemic brain injury. 
In addition, a new report shows that the activation of 
SPAK, which stimulates NKCC1 at the choroid plexus 
epithelium (CPE) apical membrane, mediates the intra-
ventricular hemorrhage (IVH)-induced hypersecretion of 
CSF in a rat model of post-hemorrhagic hydrocephalus 
(PHH) [68]. Genetic depletion of SPAK normalizes 
hyperactive CSF secretion rates and reduces PHH 
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symptoms [68]. These findings suggest that 
pharmacological targeting WNK-SPAK-CCCs signaling 
pathway presents a novel strategy to treat patients with 
hydrocephalus instead of invasive CSF shunting.  
 
The Cl– cotransporters and WNK-SPAK signaling 
pathway in other nervous system diseases  
 
In humans, mutations of KCC3 can cause Andermann 
syndrome, a Mendelian disease characterized by agenesis 
of the corpus callosum with peripheral neuropathy 
(ACCPN) [60]. T991A mutations of KCC3 in patient cells 
stop Thr (991) phosphorylation and cause constitutive 
KCC3 activity, which interferes with cell volume 
regulation [55]. Mice with KCC3T991A/T991A mutations 
displayed constitutive KCC3 activity and recapitulated 
aspects of the electrophysiological, histopathological, and 
clinical findings of peripheral neuropathy patients [55]. 
On the other hand, the “loss of function mutations” in 
KCC3 transporters, mostly due to premature termination, 
cause hereditary motor and sensory neuropathy (HMSN) 
with agenesis of the corpus callosum (ACC) [69]. The 
disorder is characterized by an early onset sensorimotor 
neuropathy associated with variable degrees of ACC. 
Individuals are affected at the rate of 1:2117 live births (in 
the regions of Charlevoix and Saguenay-Lac-Saint-Jean) 
and carry two copies of a mutant allele which causes 
KCC3 truncation (Table 1) and loss of transport activity 
[60]. There are two kinds of gene mutations of T991A and 
pT813X. KCC3 KO mouse models recapitulate the 
neuropathy phenotype of the patients [60, 61]. KCCs also 
play an important role in the maintenance of nervous 
system function. Epilepsy is a common CNS disease, and 
the patients with “loss of function mutations” of KCC3 
exhibit a lower seizure threshold, which was also 
observed in KCC3 KO mice [61]. The complex 
pathophysiology phenotypes in the nervous system 
resulting from loss-of-function or gain-of-function of 
KCC3 present challenges for developing therapeutic 
treatment by targeting KCC3. However, it is still unclear 
how KCC3 is involved in these diseases. Moreover, the 
time point when KCC3 function is critical during 
development or lifetime is still unclear. Therapeutic 
approaches specifically targeting KCC3 can be difficult 
due to a list of unknown cell types that could be 
potentially affected by KCC3 disruption [70, 71]. 
Therapies targeting KCC3 is also likely to affect the other 
KCC isoforms due to the high level of conservation in 
KCC3 among all isoforms [55, 71]. Improved gene 
therapy is needed for more specific targeting at KCC3 
without disrupting the other isoforms. 
Additional reports show that WNK gene families are 
involved in other neurological diseases. A small number 
of patients with autism revealed deletions of the WNK3 
and FAM120C genes, for which a definitive phenotype 
has not been previously characterized [72]. Additionally, 
a genetic disease known as hereditary sensory neuropathy 
(HSN) or hereditary sensory and autonomic neuropathy 
(HSAN) was initially believed to be caused by a mutation 
in a single exon open reading frame (ORF) located within 
intron 8 of the WNK1 allele, termed “HSN2” [73]. HSN2 
was later found to be a nervous system-specific alternately 
spliced exon of WNK1 as early as 2008 [74]. HSANII 
affects the peripheral and spinal nerves and results in loss 
of touch, temperature, and pain sensation [75]. 
WNK1/HSN2 contributed to a maladaptive decrease in 
the activity of the KCC2 by increasing its inhibitory 
phosphorylation at Thr906/ Thr1007, resulting in an 
associated loss of GABA-mediated inhibition of chronic 
pain hypersensitivity after nerve injury [75]. It was found 
that both genetic knockout and pharmacologic inhibition 
of WNK/HSN2 leads to amelioration of neuropathic pain 
while not producing neurological deficits [75]. These 
findings reveal therapeutic potentials of targeting WNK1 
and KCC2 for neuropathic pain after nerve injury [75]. 
However, KCC2 KO mice died immediately after birth 
due to severe motor deficits that prevented respiration 
[76]. 
 
Conclusions 
 
For decades, cell volume regulation has been a subject 
undergoing intense study. The WNK-SPAK/OSR1 kinase 
complex and Cl- cotransporters play a crucial role in 
regulating cell volume in the nervous system (Fig. 2). 
Identification of specific human gene mutations in the 
WNK-SPAK-CCC signaling pathways and development 
of genetic mouse models enhanced our understanding of 
the significance of cell volume homeostasis in nervous 
system disease development and treatment. Oxidative 
stress directly activates SPAK/OSR1, which can in turn 
regulates WNK activity, thus indirectly activates WNK 
(Fig. 2) [30]. Injuries such as peripheral nerve injury, 
spinal cord injury, and ischemic stroke are also shown to 
trigger WNK activation (Fig. 2). However, no evidence 
yet directly links inflammation to WNK activation. Gene 
mutations in WNK1 and WNK4 lead to compromised cell 
volume homeostasis and cause PHAII [77], the 
phenotypic inverse of the salt-wasting Gitelman 
syndrome (Fig. 2). Other genetic mutations in the 
ubiquitin E3 ligase components cullin 3 (CUL3) and 
kelch-like 3 (KLHL3), the upstream genes encoding 
negative regulators of WNK, increases WNK abundance 
[77-79], HSN2 gene mutations lead to a loss-of-function 
on WNK1 activity and lower the pain threshold through 
KCC2-mediated GABA hyperpolarization [75]. 
Therefore, blocking WNK-SPAK/OSR1 may provide a 
potent means of synchronously inhibiting of NKCC1-
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mediated Cl– influx and enhancing KCC-mediated Cl– 
extrusion for multiple syndromes exhibiting depolarized 
GABA responses and altered Cl– homeostasis, cerebral 
edema, or hydrocephalus. Mutations of WNK-SPAK-
CCC complex identify them as therapeutic targets for 
other nervous system or non-nervous system disorders. 
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